AlphAIAlphAI — Financial news for AI agents
benzinga.comSEP 82 min read$ISPC

Why iSpecimen Shares Are Trading Higher By Around 28%; Here Are 20 Stocks Moving Premarket - Novartis (NY

iSpecimen Inc (NASDAQ:ISPC) shares rose 27.9% to $1.97 in pre-market trading after announcing a $4.5M acquisition of Foldlab AI assets. Novartis AG (NYSE:NVS) shares fell 12.7% to $139.56 following a failed clinical trial. Other stocks also moved significantly in pre-market trading.

Original reporting
benzinga.com
Published Sep 8, 2026, 8:44 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 8, 2026, 7:59 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefMarket movers
Primary signal
$ISPC
Bullish
high confidence
Mentioned
$ISPC · $WDH · $DYN · $NVS
Relevance
6/10
AlphAI data visualization · based on benzinga.com
Decision brief

The 30-second read

$ISPCBullishHigh
01

Why it matters

Key events include iSpecimen's AI asset acquisition, Waterdrop's upcoming earnings, Dyne's data presentation, and Novartis's trial miss, each driving distinct market reactions.

02

Market read

The mix of acquisition news, earnings preview, and clinical trial outcome provides immediate trading opportunities across biotech and pharma sectors.

03

What to watch

Regulatory review of the Foldlab AI assets could delay benefits; Novartis may have pipeline offsets.

Relevance 6/10Novelty 6/10Timing: pre‑market today

Background

The article is a pre‑market mover roundup highlighting several stocks with notable price changes and upcoming catalysts.

Company-level read

Ticker impact

$ISPCBullishHigh confidence
Context

iSpecimen announced a $4.5 million acquisition of Foldlab AI assets, driving a 27.9% pre‑market jump.

Expected impact

Expect continued upside as the market digests the deal.

Evidence & confidence

Large percentage move on a concrete deal suggests strong short‑term buying pressure.

$WDHNeutralMedium confidence
Context

Waterdrop disclosed it will report its Q2 results on Sept. 8, prompting a 7.2% pre‑market gain.

Expected impact

Potential swing depending on earnings surprise.

Evidence & confidence

Upcoming earnings are a known catalyst but no results yet.

$DYNNeutralMedium confidence
Context

Dyne Therapeutics will present preclinical data for Duchenne muscular dystrophy candidates at a scientific meeting.

Expected impact

Possible upside if data exceeds expectations; downside risk if not.

Evidence & confidence

Pre‑clinical data releases are material for biotech stocks.

$NVSBearishHigh confidence
Context

Novartis reported its pelacarsen Phase III HORIZON trial missed the primary endpoint, sending the stock down 12.7% pre‑market.

Expected impact

Further declines expected until clarification on next steps.

Evidence & confidence

Phase III miss is a material event for a large pharma.

Market effects

Sector

AI acquisition highlights growing consolidation in biotech AI tools; trial failure may dampen lipid‑lowering sector sentiment.

Regional

US biotech and pharma stocks see mixed reactions; European markets largely unaffected.

Global

Large‑cap pharma news (Novartis) could influence global lipid‑therapy outlook.

Counterpoint

What could challenge this read

ISPC's high valuation post‑deal may be overblown; investors could wait for integration details.

Key entities

  • company
    iSpecimen Inc

    Biotech firm acquiring AI assets.

  • asset
    Foldlab AI

    AI models and software purchased by iSpecimen.

  • company
    Novartis AG

    Pharma giant with failed Phase III trial.

Read at source← All news

Related articles

OCT 28
$NVSHighAI 9/10

Key facts: Novartis (NOVN) Q3 revenue +4%; net profit down 70%

Novartis (NOVN) reported Q3 2026 revenue of $14.5B (+4% YoY) and adjusted EPS of $2.46, with core operating income rising 10-11%. Net profit fell 70% to $1.2B due to a $1.9B impairment. The company raised full-year core operating income guidance and highlighted remibrutinib as a key growth driver. Novartis plans small acquisitions and will host an earnings call.

tradingview.com1 min
OCT 27
$NVSHighAI 8/10

What Novartis (NVS) Said on Its Q3 Earnings Call

Novartis (NVS) raised its full-year 2026 core operating income outlook to flat to low-double-digit growth. The company reported strong sales growth for Kisqali, Kesimpta, Pluvicto, Leqvio, and Scemblix. Novartis also updated its peak-sales forecast for Rhapsido to over $4 billion. Pipeline updates included positive data for remibrutinib and setbacks for del-desiran and pelacarsen. The company repurchased $2.8 billion in shares and completed acquisitions.

finance.yahoo.com2 min
OCT 27
$NVSHighAI 8/10

Novartis AG (NVS) (Q3 2026) Earnings Call Highlights: Raised Guidance and Priority

Novartis (NVS) reported Q3 2026 earnings, raising guidance despite setbacks. Daldesiran and Pelacarsen trials failed, leading to a $1.9B impairment. Pluvicto sales were flat, and Entresto faces generic competition. CEO Narasimhan expects 2027 growth driven by Kisqali, Kesimpta, and other key drugs. The company reaffirmed a 40% core margin target by 2029, with Q4 margins expected to dip due to year-end spending.

finance.yahoo.com3 min
OCT 27
$NVSMedAI 8/10

MFN Drug Policy Cuts US Costs; It May Block Europe’s First Sjögren’s Therapy

Novartis CEO Vasant Narasimhan warned that the US Most Favored Nation (MFN) drug pricing policy may delay or block European launches of certain drugs, including ianalumab, a potential first treatment for Sjögren's disease. Novartis Q3 2026 sales rose 4% to $14.5B, with core earnings up 9% to $2.46 per share, leading to upgraded full-year guidance. The company cited MFN as a structural challenge for European drug pricing and access.

techtimes.com3 min
OCT 27
$NVSMedAI 8/10

Novartis earnings analysis: questions answered and next catalysts

Novartis (NVS) reported Q3 2026 earnings with core EPS beating estimates by 7.89% while revenue missed slightly. The company raised its profit outlook for the year. Key growth drivers include Kisqali, Kesimpta, and Leqvio, offsetting losses from generic drugs. The stock rose 1.27% to $155.76. Management expects H2 sales and core operating income to improve. Questions remain about Q4 margins and 2027 guidance.

investing.com2 min
OCT 27
$NVSMedAI 8/10

Novartis Stocks Gain With Higher Guidance but Weaker Cash Generation

Novartis (NYSE:NVS) shares rose 1.36% to $155.91 after raising its full-year core operating income forecast. Q3 core operating income grew 11% to $6.036B, but free cash flow declined 18% to $5.111B. The company recorded $2.2B in charges for unsuccessful drug programs. Investors question if improved profitability will lead to better cash flow.

finance.yahoo.com2 min